secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001193125-26-055919
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics amends Series B Preferred terms to allow board discretion to convert to common stock
--------------------------------------------------------------------------------

- On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.
- Amendment grants the board sole discretion to convert Series B Preferred into common stock using the Conversion Ratio.
- Amendment was approved by the board and by unanimous written consent of Series B holders.
- No immediate conversion; board may elect to convert in whole or in part at a later date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526055919/0001193125-26-055919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526055919/d60666d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-055919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer